Disposition and metabolism of Setipiprant, a selective oral CRTH2 antagonist, in humans

Drugs in R and D

Volumn 13, Issue 4, 2013, Pages 253-269

  Hoch, Matthias ^a   Wank, Janine ^b   Kluge, Ina ^b   Wagner Redeker, Winfried ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Swiss BioAnalytics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOLINE DERIVATIVE; CARBON 14; DRUG METABOLITE; EPOXIDE; NAPHTHALENE DERIVATIVE; SETIPIPRANT;

ABDOMINAL DISCOMFORT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; EPOXIDATION; FECES; FECES COLOR; HEADACHE; HUMAN; HUMAN EXPERIMENT; ISOMER; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA; PRIORITY JOURNAL; RADIOACTIVITY; RING OPENING; SIDE EFFECT; SINGLE DRUG DOSE; URINE;

ADMINISTRATION, ORAL; AGED; CARBON RADIOISOTOPES; FECES; HUMANS; INDOLES; MALE; MIDDLE AGED; NAPHTHALENES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 84896498044     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0031-7     Document Type: Article

References (7)

1. Arima M, Fukuda T. Prostaglandin D2 receptors DP and CRTH2 in the pathogenesis of asthma. Curr Mol Med. 2008;8(5):365-75.
2. Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85(6):372-82.
3. Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi K, et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol. 2006;177(4):2621-9. (Pubitemid 44201021)
4. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006;12(4):148-58.
5. Diamant Z, Singh D, O'Connor B, Zuiker R, Ponnarambil S, Leaker B, et al. Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients. Am J Respir Crit Care Med 185;2012:A3957.
6. Company press release: Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis. http://www.actelion.com. Accessed 23 May 2011.
7. Company press release: Actelion provides update on CRTH2 program. http://www.actelion.com. Accessed 2 April 2012.